Drug Profile
Research programme: DepoVax-based malaria vaccine - IMV/University of Edinburgh
Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator University of Edinburgh
- Developer IMV; University of Edinburgh
- Class Antiparasitics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 07 Sep 2023 Discontinued - Preclinical for Malaria (Prevention) in USA (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Malaria(Prevention) in USA (Parenteral)
- 03 May 2018 Immunovaccine is now called IMV